Beam Therapeutics IncNASDAQ:BEAM
- LAST PRICE27.0600
- TODAY'S CHANGE (%)0.9600 (3.6782%)
- Bid / Lots25.1000/ 1
- Ask / Lots27.3500/ 1
- Open / Previous Close25.8800 / 26.1000
- Day Range
- 52 Week Range
- Volume1,266,095
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BEAM |
|---|---|---|
| 09:32 ET | 5524 | 25.875 |
| 09:33 ET | 300 | 25.6765 |
| 09:37 ET | 100 | 25.8808 |
| 09:39 ET | 1569 | 26.1 |
| 09:42 ET | 1038 | 26.14 |
| 09:44 ET | 4848 | 26.06 |
| 09:46 ET | 980 | 26.125 |
| 09:48 ET | 2375 | 26.29 |
| 09:50 ET | 3179 | 26.5 |
| 09:51 ET | 1209 | 26.465 |
| 09:53 ET | 1640 | 26.295 |
| 09:55 ET | 663 | 26.47 |
| 09:57 ET | 1168 | 26.54 |
| 10:00 ET | 4412 | 26.6155 |
| 10:02 ET | 1588 | 26.62 |
| 10:04 ET | 2610 | 26.63 |
| 10:06 ET | 2518 | 26.74 |
| 10:08 ET | 2551 | 26.66 |
| 10:09 ET | 6321 | 26.71 |
| 10:11 ET | 1709 | 26.76 |
| 10:13 ET | 12364 | 26.93 |
| 10:15 ET | 1000 | 26.86 |
| 10:18 ET | 3358 | 26.85 |
| 10:20 ET | 786 | 26.7746 |
| 10:22 ET | 558 | 26.72 |
| 10:24 ET | 100 | 26.67 |
| 10:26 ET | 600 | 26.52 |
| 10:27 ET | 1000 | 26.54 |
| 10:29 ET | 2843 | 26.68 |
| 10:31 ET | 200 | 26.69 |
| 10:33 ET | 778 | 26.7 |
| 10:36 ET | 4310 | 26.74 |
| 10:38 ET | 300 | 26.74 |
| 10:40 ET | 3900 | 26.78 |
| 10:42 ET | 1100 | 26.75 |
| 10:44 ET | 1104 | 26.845 |
| 10:45 ET | 900 | 26.795 |
| 10:47 ET | 1710 | 26.79 |
| 10:49 ET | 3915 | 26.8 |
| 10:51 ET | 400 | 26.82 |
| 10:54 ET | 1377 | 26.6975 |
| 10:56 ET | 700 | 26.66 |
| 10:58 ET | 1500 | 26.6665 |
| 11:02 ET | 100 | 26.66 |
| 11:03 ET | 100 | 26.55 |
| 11:05 ET | 1100 | 26.47 |
| 11:07 ET | 1419 | 26.525 |
| 11:09 ET | 1347 | 26.49 |
| 11:12 ET | 200 | 26.44 |
| 11:14 ET | 2735 | 26.49 |
| 11:16 ET | 1175 | 26.445 |
| 11:18 ET | 100 | 26.49 |
| 11:20 ET | 630 | 26.505 |
| 11:21 ET | 500 | 26.6 |
| 11:23 ET | 1240 | 26.635 |
| 11:25 ET | 899 | 26.645 |
| 11:27 ET | 212 | 26.65 |
| 11:30 ET | 100 | 26.64 |
| 11:32 ET | 228 | 26.62 |
| 11:34 ET | 705 | 26.64 |
| 11:36 ET | 700 | 26.58 |
| 11:38 ET | 500 | 26.635 |
| 11:39 ET | 300 | 26.665 |
| 11:41 ET | 100 | 26.73 |
| 11:43 ET | 350 | 26.6201 |
| 11:45 ET | 200 | 26.7075 |
| 11:48 ET | 335 | 26.655 |
| 11:50 ET | 927 | 26.72 |
| 11:52 ET | 520 | 26.73 |
| 11:54 ET | 100 | 26.76 |
| 11:56 ET | 100 | 26.73 |
| 11:57 ET | 433 | 26.75 |
| 11:59 ET | 200 | 26.725 |
| 12:03 ET | 1168 | 26.745 |
| 12:06 ET | 200 | 26.75 |
| 12:08 ET | 588 | 26.63 |
| 12:10 ET | 500 | 26.61 |
| 12:12 ET | 100 | 26.62 |
| 12:14 ET | 1800 | 26.5 |
| 12:15 ET | 1372 | 26.455 |
| 12:17 ET | 901 | 26.5 |
| 12:19 ET | 868 | 26.54 |
| 12:21 ET | 779 | 26.5743 |
| 12:24 ET | 1000 | 26.55 |
| 12:26 ET | 100 | 26.545 |
| 12:28 ET | 1298 | 26.56 |
| 12:30 ET | 100 | 26.53 |
| 12:32 ET | 464 | 26.51 |
| 12:33 ET | 300 | 26.53 |
| 12:35 ET | 2274 | 26.56 |
| 12:37 ET | 100 | 26.57 |
| 12:39 ET | 110 | 26.56 |
| 12:44 ET | 1260 | 26.535 |
| 12:46 ET | 934 | 26.59 |
| 12:48 ET | 100 | 26.59 |
| 12:50 ET | 1440 | 26.53 |
| 12:51 ET | 2201 | 26.5 |
| 12:53 ET | 7708 | 26.39 |
| 12:55 ET | 1200 | 26.45 |
| 12:57 ET | 500 | 26.45 |
| 01:00 ET | 1428 | 26.4 |
| 01:02 ET | 1500 | 26.4 |
| 01:04 ET | 200 | 26.415 |
| 01:06 ET | 3100 | 26.4 |
| 01:08 ET | 1900 | 26.455 |
| 01:09 ET | 200 | 26.48 |
| 01:11 ET | 207 | 26.45 |
| 01:13 ET | 745 | 26.45 |
| 01:15 ET | 755 | 26.45 |
| 01:18 ET | 2800 | 26.42 |
| 01:20 ET | 500 | 26.51 |
| 01:22 ET | 1000 | 26.475 |
| 01:24 ET | 6173 | 26.495 |
| 01:26 ET | 2400 | 26.51 |
| 01:27 ET | 6303 | 26.525 |
| 01:29 ET | 950 | 26.52 |
| 01:31 ET | 3357 | 26.84 |
| 01:33 ET | 3686 | 26.77 |
| 01:36 ET | 2518 | 26.85 |
| 01:38 ET | 4004 | 26.77 |
| 01:40 ET | 200 | 26.83 |
| 01:44 ET | 1176 | 26.82 |
| 01:45 ET | 5904 | 26.97 |
| 01:47 ET | 815 | 26.955 |
| 01:49 ET | 5257 | 26.98 |
| 01:51 ET | 1000 | 27 |
| 01:54 ET | 1200 | 27 |
| 01:56 ET | 509 | 27.025 |
| 01:58 ET | 4014 | 27.02 |
| 02:00 ET | 2284 | 26.94 |
| 02:02 ET | 2421 | 26.87 |
| 02:03 ET | 100 | 26.86 |
| 02:05 ET | 1844 | 26.835 |
| 02:07 ET | 600 | 26.88 |
| 02:09 ET | 704 | 26.92 |
| 02:12 ET | 1023 | 26.93 |
| 02:14 ET | 1100 | 26.88 |
| 02:16 ET | 936 | 26.91 |
| 02:18 ET | 3800 | 26.85 |
| 02:20 ET | 1237 | 26.81 |
| 02:23 ET | 300 | 26.8 |
| 02:25 ET | 1313 | 26.88 |
| 02:27 ET | 15216 | 26.94 |
| 02:30 ET | 3231 | 27.07 |
| 02:32 ET | 1441 | 27.065 |
| 02:34 ET | 100 | 27.05 |
| 02:36 ET | 200 | 27.06 |
| 02:38 ET | 1868 | 27.1 |
| 02:39 ET | 100 | 27.1 |
| 02:41 ET | 200 | 27.09 |
| 02:43 ET | 600 | 27.06 |
| 02:45 ET | 710 | 27.05 |
| 02:48 ET | 3669 | 27.035 |
| 02:50 ET | 475 | 27.05 |
| 02:52 ET | 1518 | 27.05 |
| 02:54 ET | 1100 | 27.01 |
| 02:56 ET | 700 | 26.99 |
| 02:57 ET | 3836 | 26.94 |
| 02:59 ET | 200 | 26.91 |
| 03:01 ET | 1883 | 26.785 |
| 03:03 ET | 1400 | 26.82 |
| 03:06 ET | 2400 | 26.84 |
| 03:08 ET | 2525 | 26.86 |
| 03:10 ET | 3527 | 26.81 |
| 03:12 ET | 1849 | 26.9 |
| 03:14 ET | 401 | 26.85 |
| 03:15 ET | 300 | 26.89 |
| 03:17 ET | 502 | 26.92 |
| 03:19 ET | 2043 | 26.9533 |
| 03:21 ET | 729 | 26.89 |
| 03:24 ET | 1857 | 26.89 |
| 03:26 ET | 3608 | 26.997 |
| 03:28 ET | 1806 | 27.03 |
| 03:30 ET | 1463 | 27.15 |
| 03:32 ET | 869 | 27.16 |
| 03:33 ET | 4293 | 27.1304 |
| 03:35 ET | 2700 | 27.225 |
| 03:37 ET | 1903 | 27.215 |
| 03:39 ET | 9325 | 27.285 |
| 03:42 ET | 2600 | 27.3 |
| 03:44 ET | 1610 | 27.34 |
| 03:46 ET | 3870 | 27.339 |
| 03:48 ET | 5844 | 27.29 |
| 03:50 ET | 2068 | 27.23 |
| 03:51 ET | 4083 | 27.23 |
| 03:53 ET | 6208 | 27.23 |
| 03:55 ET | 6175 | 27.255 |
| 03:57 ET | 14476 | 27.075 |
| 04:00 ET | 480052 | 27.06 |
Nov 7, 2024
DJ Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
DJ Beam Therapeutics Is Maintained at Sector Perform by RBC Capital, from 11:10AM ET on Wednesday Nov 06, 2024 by Dow Jones
11:10AM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Beam Therapeutics Raised to Outperform From Market Perform by Leerink Partners, from 7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Press Release: Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting, from 9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:00AM ET on Tuesday Nov 05, 2024 by Dow JonesBeam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting, from 9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beam Therapeutics Inc | 2.2B | -15.7x | --- |
Genmab A/S | 15.3B | 22.5x | +22.71% |
Galapagos NV | 1.8B | -27.8x | --- |
Veracyte Inc | 2.8B | -49.0x | --- |
Catalyst Pharmaceuticals Inc | 2.9B | 20.4x | --- |
BioCryst Pharmaceuticals Inc | 1.6B | -12.8x | --- |
Company Information
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Contact Information
- Headquarters
- 238 Main StreetCAMBRIDGE, MA, United States 02142
- Phone
- 857-327-8775
- Fax
- 302-655-5049
Executives
- President
- Giuseppe Ciaramella
- Chief Executive Officer, Principal Financial and Accounting Officer, Director
- John Evans
- Chief Medical Officer
- Amy Simon
- Chief Legal Officer and Secretary
- Christine Bellon
- Lead Independent Director
- Mark Fishman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
|---|---|
Revenue (TTM) | $349.6M |
Shares Outstanding | 82.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.90 |
EPS | $-1.72 |
Book Value | $12.02 |
P/E Ratio | -15.7x |
Price/Sales (TTM) | 6.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -52.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
